Affinity Asset Advisors LLC Invests $11.88 Million in Eliem Therapeutics, Inc. (NASDAQ:ELYM)

Affinity Asset Advisors LLC bought a new stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 1,670,661 shares of the company’s stock, valued at approximately $11,878,000. Eliem Therapeutics comprises about 1.4% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 20th largest holding. Affinity Asset Advisors LLC owned 5.62% of Eliem Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. Rhumbline Advisers bought a new position in shares of Eliem Therapeutics during the 2nd quarter worth approximately $59,000. Dimensional Fund Advisors LP purchased a new position in Eliem Therapeutics in the second quarter worth $89,000. Bank of New York Mellon Corp acquired a new position in shares of Eliem Therapeutics during the second quarter worth $134,000. Renaissance Technologies LLC lifted its holdings in shares of Eliem Therapeutics by 248.5% during the 2nd quarter. Renaissance Technologies LLC now owns 37,000 shares of the company’s stock valued at $263,000 after purchasing an additional 26,383 shares during the last quarter. Finally, Ally Bridge Group NY LLC purchased a new stake in shares of Eliem Therapeutics during the 2nd quarter valued at $3,555,000. 69.76% of the stock is currently owned by institutional investors.

Eliem Therapeutics Stock Performance

Shares of ELYM stock opened at $6.56 on Wednesday. The stock’s fifty day moving average price is $7.26 and its 200 day moving average price is $6.49. Eliem Therapeutics, Inc. has a 1-year low of $2.35 and a 1-year high of $11.55.

Eliem Therapeutics (NASDAQ:ELYM) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($1.81) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In related news, EVP Valerie Morisset sold 69,005 shares of the company’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $8.03, for a total value of $554,110.15. Following the transaction, the executive vice president now directly owns 31,317 shares of the company’s stock, valued at approximately $251,475.51. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, EVP Valerie Morisset sold 69,005 shares of the stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $8.03, for a total value of $554,110.15. Following the transaction, the executive vice president now directly owns 31,317 shares of the company’s stock, valued at $251,475.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. bought 13,008,546 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The stock was purchased at an average price of $3.84 per share, for a total transaction of $49,952,816.64. Following the transaction, the director now owns 23,521,757 shares of the company’s stock, valued at $90,323,546.88. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 294,254 shares of company stock valued at $2,137,260. Insiders own 4.70% of the company’s stock.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.